The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
Open accessAbstract
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain. Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks. Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United States. Patients (n = 1822) with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma who had at least 1 site of bone involvement were enrolled between May 2009 and April 2012; follow-up concluded in April 2014. Interventions: Patients were randomized to receive zoledronic acid administered intravenously every 4 weeks (n = 911) vs every 12 weeks (n = 911) for 2 years. Main Outcomes and Measures: The primary end point was the proportion of patients having at least 1 skeletal-related event (defined as clinical fracture, spinal cord compression, radiation to bone, or surgery involving bone) within 2 years after randomization and a between-group absolute difference of 7% as the noninferiority margin. Secondary end points included the proportion of patients with at least 1 skeletal-related event by disease type, pain as assessed by the Brief Pain Inventory (range, 0-10; higher scores indicate worse pain), Eastern Cooperative Oncology Group performance status (range, 0-4; higher scores indicate worse disability), incidence of osteonecrosis of the jaw, kidney dysfunction, skeletal morbidity rate (mean number of skeletal-related events per year), and, in a subset of 553 patients, suppression of bone turnover (assessed by C-terminal telopeptide levels). Results: Among 1822 patients who were randomized (median age, 65 years; 980 [53.8%] women; 855 with breast cancer, 689 with prostate cancer, and 278 with multiple myeloma), 795 completed the study at 2 years. A total of 260 patients (29.5%) in the zoledronic acid every 4-week dosing group and 253 patients (28.6%) in the every 12-week dosing group experienced at least 1 skeletal-related event within 2 years of randomization (risk difference of -0.3% [1-sided 95% CI, -4% to ∞]; P < .001 for noninferiority). The proportions of skeletal-related events did not differ significantly between the every 4-week dosing group vs the every 12-week dosing group for patients with breast cancer, prostate cancer, or multiple myeloma. Pain scores, performance status scores, incidence of jaw osteonecrosis, and kidney dysfunction did not differ significantly between the treatment groups. Skeletal morbidity rates were numerically identical in both groups, but bone turnover was greater (C-terminal telopeptide levels were higher) among patients who received zoledronic acid every 12 weeks. Conclusions and Relevance: Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, the use of zoledronic acid every 12 weeks compared with the standard dosing interval of every 4 weeks did not result in an increased risk of skeletal events over 2 years. This longer interval may be an acceptable treatment option. Trial Registration: clinicaltrials.gov Identifier: NCT00869206.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A lower intensity schedule every 3–4 months may provide similar protection with less side effects compared to monthly administration.188”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [188]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Everitt, B. S. (2001) · Psychology Press eBooks · doi:10.4324/9781410605542-11 · Cited by 6,877
Pain assessment: global use of the Brief Pain Inventory.
Cs, C., & Km, R. (1994) · PubMed · Cited by 5,178
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Fred Saad, C., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P. N., Lacombe, L., Chin, J. L., Vinholes, J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,648
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., PAPADIMITRIOU, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8670 · Cited by 1,136
Rosen, L. S., Gordon, D., Tchekmedyian, S., Yanagihara, R. H., Hirsh, V., Krzakowski, M. J., Pawlicki, M., SOUZA, P. D., Zheng, M., Urbanowitz, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.105 · Cited by 728
The randomization and stratification of patients to clinical trials
Zelen, M. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90015-0 · Cited by 614
Research works printed but not linked: 1
- [17]National Research Council Panel on Handling Missing Data in Clinical Trials The Prevention and Treatment of Missing Data in Clinical Trials Washington, DC National Academies Press 2010 24983040
Cited by
Sorted by citations
Items 301–356 of 356
Roadmap for new practitioners to navigate the multiple myeloma landscape
Tam, T., Smith, E. L., Lozoya, E., Heers, H. M., & Allred, P. A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10586 · Cited by 1
Osteoonkologie: Knochenmetastasen und Tumortherapie-induzierte Osteoporose
Diel, I., Jehn, C.-F., & Rachner, T. D. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_195-1
Hupe, M. C., Müller, M., Struck, J. P., Wießmeyer, J. R., Ozimek, T., Steuber, T. P., Gschwend, J. E., Hammerer, P., Kramer, M. W., & Merseburger, A. S. (2022) · TumorDiagnostik & Therapie · doi:10.1055/a-1892-4251
Brust- und gynäkologische Tumoren – medikamentöse Therapie ossärer Metastasen
Sommer, K., Wulf, S., & Gallwas, J. K. S. (2023) · Frauenheilkunde up2date · doi:10.1055/a-1931-5820
Moderne Aspekte der Osteoprotektion – Rationale und derzeitiger Status
Casuscelli, J. (2023) · Springer eBooks · doi:10.1007/978-3-662-67297-6_11
Anti-osteoporosis drugs and reduction of mortality in cancer patients
Chandran, M., & Lau, T. C. (2024) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.20244
Systemic Therapy for Breast Cancer
Hallmeyer, S., Qamar, R., & Shamah, C. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93249-3.00009-6
Arora, M., & Chew, H. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-52001-3_5
Bone-modifying agents for bone metastasis in patients with breast cancer
Park, L. C., & Lee, E. (2024) · Kosin Medical Journal · doi:10.7180/kmj.24.121
Babeau, A. (2024) · Revue du Rhumatisme · doi:10.1016/j.rhum.2024.08.002
Significance of zoledronic acid in the adjuvant therapy in patients with breast cancer
Pietrzykowska, J., Billewicz, M., Lis, L., Popiołek, A., Marczyk, A., Turek, A., Makowska, K., & Zatorska, O. (2024) · Polish Journal of Public Health · doi:10.12923/2083-4829/2024-0009
Sood, T., & Sood, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-5357-4_15
Bone metastases, medical treatment
Coleman, R. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00163-1
Husum, Y. S., Moe, M. C., Fagerland, M. W., Eriksen, E. F., & Jørstad, Ø. K. (2024) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2024-001964 · Cited by 1
Praska, T., Griswold, C. R., Noyes, M., Mina, L. A., McGary, A. K., Yu, C., & Raheem, F. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5068799
Bone metastases; clinical aspects
Wood, S. L., Arikrishnan, A., D’Oronzo, S., & Brown, J. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00182-5
Rousseau, J., & Confavreux, C. B. (2025) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(25)76302-9
Myélome multiple : ce que le rhumatologue doit savoir en 2025
Belkhir, R. (2025) · Revue du Rhumatisme · doi:10.1016/j.rhum.2025.01.022
Gori, S., Fabi, A., Procopio, G., Airoldi, M., Zambelli, A., Lanzetta, G., Sergio Bracarda, A., Foglietta, J., Leo, S., Baggi, A., et al. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00343-5
Aimono, Y., Sunaga, T., Yonezawa, R., Tsuboya, A., Kogo, M., Tsuge, S., Tamura, A., & Itoh, A. (2025) · Cureus · doi:10.7759/cureus.84126
Finch, M., & Jacques, R. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251349490
Ha, J., Choi, S., Park, S., Moon, S., Han, J., Lee, J., Baek, K., Han, S., & Min, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-09811-4
Lavezzi, E., & Jaafar, S. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01649-2
Mel, S. D., Tso, A. C. Y., Soekojo, C. Y., Ooi, M. G. M., Lim, C. C., Teo, C., Chen, Y. X., Tan, M. S. Y., Manjeri, A., Lee, Z. Y., et al. (2025) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202532 · Cited by 1
Alaklabi, S., Refaei, S. A., Abualkhair, O., Abusanad, A. M., Akhtar, S., Al‐Foheidi, M., Al‐Hajeili, M., Al‐Tweigeri, T., Al-Hashem, H., Almufti, R., et al. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00404-9
Mori, M., Nishizawa, C., Usami, Y., Takahata, S., Matsushita, Y., Isomura, E. T., Tanaka, S., Kogo, M., Aikawa, T., & Miyagawa, K. (2025) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2025.12.007
Nakata, M., Urabe, F., Imai, Y., Iwatani, K., Inaba, Y., Nakano, J., Fujiwara, K., Hashimoto, M., Koike, Y., Iwamoto, Y., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02937-5
Rosen, D. B., Benjamin, C. D., Yang, J. C., Doyle, C., Zhang, Z., Barker, C. A., Vaynrub, M., Yang, T. J., & Gillespie, E. (2020) · Figshare · doi:10.6084/m9.figshare.13250858
Rosen, D. B., Benjamin, C. D., Yang, J. C., Doyle, C., Zhang, Z., Barker, C. A., Vaynrub, M., Yang, T. J., & Gillespie, E. (2020) · Figshare · doi:10.6084/m9.figshare.13250852
Rosen, D. B., Benjamin, C. D., Yang, J. C., Doyle, C., Zhang, Z., Barker, C. A., Vaynrub, M., Yang, T. J., & Gillespie, E. (2020) · Figshare · doi:10.6084/m9.figshare.13250867
Rosen, D. B., Benjamin, C. D., Yang, J. C., Doyle, C., Zhang, Z., Barker, C. A., Vaynrub, M., Yang, T. J., & Gillespie, E. (2020) · Figshare · doi:10.6084/m9.figshare.13250861
Huang, Q., Liu, M., Zhang, D., Lin, B.-B., Fu, X., Zhang, Z., Zhang, B., & Dong, J.-T. (2023) · Figshare · doi:10.6084/m9.figshare.22607072
Huang, Q., Liu, M., Zhang, D., Lin, B.-B., Fu, X., Zhang, Z., Zhang, B., & Dong, J.-T. (2023) · Figshare · doi:10.6084/m9.figshare.22607069
Zhou, Q., Chen, X., Yao, K., Zhang, Y., He, H., Huang, H., Chen, H., Peng, S., Huang, M., Liang Cheng, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23884387
Lim, A. R., Park, W., Moon, S. J., Kim, M. S., & Lee, S. H. (2024) · Figshare · doi:10.6084/m9.figshare.26701453
Rosen, D. B., Benjamin, C. D., Yang, J. C., Doyle, C., Zhang, Z., Barker, C. A., Vaynrub, M., Yang, T. J., & Gillespie, E. (2020) · Figshare · doi:10.6084/m9.figshare.13250864
Huang, Q., Liu, M., Zhang, D., Lin, B.-B., Fu, X., Zhang, Z., Zhang, B., & Dong, J.-T. (2023) · Figshare · doi:10.6084/m9.figshare.22607066
Rosen, D. B., Benjamin, C. D., Yang, J. C., Doyle, C., Zhang, Z., Barker, C. A., Vaynrub, M., Yang, T. J., & Gillespie, E. (2020) · Figshare · doi:10.6084/m9.figshare.13250855
Some clinical aspects of antiresorptive treatment in patients with bone metastases
Kozlovskaya, A. V., & Galin, A. P. (2025) · Yakut Medical Journal · doi:10.25789/ymj.2025.92.27
Is strict use of denosumab or zoledronate Beneficial to patients with bone metastatic Disease?
Lin, C.-W., Wang, H.-Y., Yu, C.-E., Yen, H., Lin, W.-H., Fu, S., Ko, J.-C., & Chen, C. (2026) · Journal of bone oncology · doi:10.1016/j.jbo.2026.100756
Chen, J., & Wu, J. Y. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag065
Xiong, Z., Zhou, G., Zhou, N., Wang, L., Liu, G., Zhang, Q., & Lyu, G. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1810319
Bone-modifying therapy in multiple myeloma: a comprehensive review
Patekar, M. B., Milunović, V., Smoljanović, I. M., Bašić‐Kinda, S., Kolonić, S. O., Radić-Krišto, D., Gašparov, S., & Baljević, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1722230
Bader, G., Brown, B., Davenport, A. P., Gatti-Mays, M. E., Johnson, K. C., Lopetegui‐Lia, N., Quiroga, D., Roy, A. M., Sardesai, S. D., Stover, D. G., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1823973
Mechanisms of breast cancer dormancy in bone metastasis
Price, M. L., Zhou, J., Maitre, C. L. L., Quayle, L. A., & Ottewell, P. D. (2026) · Clinical & Experimental Metastasis · doi:10.1007/s10585-026-10412-2
Yu, H., Yuan, X., Li, X., Tong, J., Huang, C., You, X., & Wu, J. (2026) · Neurobiology of Pain · doi:10.1016/j.ynpai.2026.100226
Anti-resorptive agents in neuroendocrine bone metastases – A systematic review
Elston, M. S., Chui, C. C., Tamatea, J. A. U., Lawrence, B., & Boyle, V. (2026) · Journal of bone oncology · doi:10.1016/j.jbo.2026.100789
Gundesen, M. T., Vangsted, A. J., Helleberg, C., Haukås, E., Silkjær, T., Madsen, J. S., Asmussen, J. T., Teodorescu, E. M., Jensen, B. A., Slørdahl, T. S., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70612
Trần, N. Q., Joung, J. Y., Thai, K. L., Truong, H. T. T., & Dai, H. P. V. (2026) · Prostate International · doi:10.1016/j.prnil.2026.08.002
Barbosa, S., Silva, M. C., Souza, M. B., Crestana, G. F., Faot, F., Bezinelli, L. M., Shibli, J. A., & Faverani, L. P. (2026) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2026rw2547
Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 3
Lyu, S., & Zhou, D. (2026) · Journal of bone oncology · doi:10.1016/j.jbo.2026.100799
Congchen, L., Yuan, Z., Xinlong, W., & Lei, Z. (2026) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2026.09.017
Racial Disparities in the Management of Myeloma Bone Disease: A Retrospective Cohort Study
Irimia, R. M., Goularte, V., Balev, M., Singel, M., Skoloda, D., Imus, P. H., Huff, C. A., Ali, S. A., Tsai, H., & Gocke, C. B. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00935
Practice patterns in myeloma bone disease: a multi-center survey
Schmidt, T. M., Gennette, R., Cole, C., Merino, A. M., Dima, D., Surapaneni, M., Shaikh, H. G., Umyarova, E. R., D'Angelo, C. R., Sánchez, M., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1948667
Salpagarov, A.-K. Y., Олеговна, С. Л., Korovin, I. A., Martynov, V. N., Grinin, V. M., & Шайхалиев, А. И. (2026) · Stomatology · doi:10.17116/stomat202610505195
Metadata
- Authors
- Himelstein, A. L., Foster, J. C., Khatcheressian, J. L., Roberts, J. D., Seisler, D. K., Novotny, P. J., Qin, R., Go, R. S., Grubbs, S. S., O’Connor, T., Velasco, M. R., Weckstein, D., O’Mara, A., Loprinzi, C. L., & Shapiro, C. L.
- Affiliations
- Helen F. Graham Cancer Center & Research Institute, Newark, Delaware
- Mayo Clinic (US)
- Virginia Cancer Institute (US)
- Virginia Commonwealth University (US)
- Gundersen Health System (US)
- American Society of Clinical Oncology (US)
- Roswell Park Comprehensive Cancer Center (US)
- Decatur Memorial Hospital (US)
- Hematology\Oncology Clinic (US)
- National Cancer Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Himelstein, Andrew L.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-01-03
- Volume
- 317
- Issue
- 1
- Pages
- 48
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5321662
- OpenAlex
- W2562306819
- Cited by
- 356
- References
- 22
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 32 · 2023: 26 · 2022: 31 · 2021: 48 · 2020: 49 · 2019: 56 · 2018: 27 · 2017: 26
- FWCI
- 19.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Pfizer
- Gilead Sciences
- National Institutes of Health (UL1TR001070, UL1TR001863)
- National Cancer Institute (UG1CA189850, U10CA077440, U10CA035279, U10CA074811, UG1CA189823, UG1CA189805, U10CA037447, UG1CA189825, UG1CA189853, U10CA047559, UG1CA189830, U10CA180836, UG1CA189817, U10CA059518, U10CA180866, U10CA035272, U10CA180790, U10CA037404, U10CA052784, U10CA180857, U10CA047577, UG1CA232760, UG1CA189861, U10CA045418, U10CA180850, U10CA180867, U10CA041287, U10CA077658, UG1CA189870, UG1CA189819, P30CA016359)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- zoledronic acid, dosing interval, extended dosing, skeletal-related events, bone metastasis, bisphosphonates, non-inferiority, metastatic breast cancer, metastatic prostate cancer, multiple myeloma, bone pain, osteonecrosis of the jaw, renal dysfunction, bone turnover suppression, C-terminal telopeptide, fracture, spinal cord compression
- MeSH terms
- Zoledronic Acid, Adult, Aged, Aged, 80 and over, Bone and Bones, Bone Neoplasms, Breast Neoplasms, Diphosphonates, Drug Administration Schedule, Female, Humans, Imidazoles, Male, Middle Aged, Multiple Myeloma, Pain Measurement, Prostatic Neoplasms, Spinal Cord Compression, Spinal Fractures, Sample Size, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
